Acyl substituted insulins
    12.
    发明授权
    Acyl substituted insulins 失效
    ACYL替代胰岛素

    公开(公告)号:US3755569A

    公开(公告)日:1973-08-28

    申请号:US3755569D

    申请日:1972-07-25

    CPC分类号: C07K14/625 A61K38/00

    摘要: ACYL-SUBSTITUTED-INSULINS, PARTICULARLY PHENYL- AND SUBSTITUTED-PHENYLGLYCYL-INSULINS, ESPECIALLY N-PHENYLGLYCYLINSULIN, N-P-METHYLPHENYLGLYCLY-INSULIN AND N-P-CHLOROPHENYLGLYCOL-INSULIN (I), ARE PREPARED BY TREATING INSULIN WITH AN ACYLATING AGENT, ESPECIALLY THE CORRESPONDING NCHLOROFORMYL-N-PHENYL OR SUBSTITUTED-PHENYLGLYCIN. (II). THE NEW COMPOUNDS (I) HAVE HYPOGLYCEMIC ACTIVITY AND ARE USEFUL TO TREAT DIAMBETES, ESPECIALLY IN SUBJECTS WHO ARE INSULIN FAST.

    Composition and method of using a protein mixture derived from liver
    13.
    发明授权
    Composition and method of using a protein mixture derived from liver 失效
    使用衍生自肝脏的蛋白质混合物的组成和方法

    公开(公告)号:US4024247A

    公开(公告)日:1977-05-17

    申请号:US565864

    申请日:1975-04-07

    IPC分类号: C07K2/00 A61K17/02 A61K27/00

    CPC分类号: C07K2/00

    摘要: A composition of matter and method useful in treating certain disease conditions by virtue of a protein mixture having a variety of disparate properties, such as facilitating wound healing and influencing glucose metabolism. It also exhibits pronounced superoxide dismutase activity. The composition may supplant or be combined with cortico-steroids to provide anti-inflammatory response while facilitating wound healing. It increases the rate of urea nitrogen synthesis, reduces peripheral blood ammonia, simultaneously facilitates glucose uptake and glycogen deposition. It is useful for treating hepatitis, arthritis, and scar tissue.

    摘要翻译: 通过具有多种不同性质的蛋白质混合物治疗某些疾病状况的物质和方法的组合物,例如促进伤口愈合和影响葡萄糖代谢。 它还具有显着的超氧化物歧化酶活性。 组合物可以取代或与皮质类固醇组合以提供抗炎反应,同时促进伤口愈合。 提高尿素氮合成速度,减少外周血氨,同时促进葡萄糖摄取和糖原沉积。 它可用于治疗肝炎,关节炎和瘢痕组织。

    Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
    14.
    发明授权
    Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin 失效
    单 - ,二和N {HD A1 {B,N {HU B1 {B,N {HU B29 {B-三酰基化胰岛素

    公开(公告)号:US3869437A

    公开(公告)日:1975-03-04

    申请号:US39021673

    申请日:1973-08-21

    申请人: NAT RES DEV

    CPC分类号: C07K14/62 A61K38/00

    摘要: A physiologically acceptable insulin derivative has the terminal amino group of the B chain (B1, phenylalanine) protected by an acyl group or other blocking group containing up to seven carbon atoms and the amino group of the A chain (A1, glycine) is either free or protected by means of an acyl or other blocking group containing no more than four carbon atoms and preferably no more than three atoms other than hydrogen. Pharmaceutical preparations may be prepared containing an effective amount of such an insulin derivative together with a physiologically acceptable diluent. An insulin derivative of reduced antigenicity is obtainable from porcine or bovine insulin by reacting the insulin with an acylating agent or other blocking reagent to acylate or otherwise block the amino group of the B1 amino acid and optionally block the A1 and/or B29 amino acid, followed by purification of the derivative by various methods.

    摘要翻译: 生理上可接受的胰岛素衍生物具有由酰基或其它含有至多7个碳原子的封闭基保护的B链(B1,苯丙氨酸)的末端氨基,A链(A1,甘氨酸)的氨基是游离的 或通过含有不超过四个碳原子,优选不超过三个除了氢原子的酰基或其它封闭基团来保护。 可以制备含有有效量的这种胰岛素衍生物和生理上可接受的稀释剂的药物制剂。 降低抗原性的胰岛素衍生物可通过使胰岛素与酰化剂或其它阻断试剂反应来从猪或牛胰岛素获得,以酰化或以其它方式阻断B1氨基酸的氨基并任选地阻断A1和/或B29氨基酸, 然后用各种方法纯化衍生物。

    Alkanedioic acid derivatives of insulin
    15.
    发明授权
    Alkanedioic acid derivatives of insulin 失效
    胰岛素的烷二酸衍生物

    公开(公告)号:US3868357A

    公开(公告)日:1975-02-25

    申请号:US22106072

    申请日:1972-01-26

    申请人: NAT RES DEV

    摘要: Insulin derivatives which are water soluble, readily isolated, immunologically acceptable and which retain hypoglycaemic activity are those in which at least one of the A1, B1 and B29 aminoacid amino groups is converted into a blocked amino group having a substituent capable of forming an anion, e.g., by substitution with dicarboxylic acid radicals.

    摘要翻译: 水溶性,易分离,免疫学可接受且保持低血糖活性的胰岛素衍生物是其中A1,B1和B29氨基酸氨基中的至少一个转化为具有能够形成阴离子的取代基的封闭氨基的那些, 例如,用二羧酸基取代。

    Quick-acting,stable,neutral solution of bovine insulin and process for the production thereof
    16.
    发明授权
    Quick-acting,stable,neutral solution of bovine insulin and process for the production thereof 失效
    牛肉胰岛素的快速,稳定,中性解决方案及其生产方法

    公开(公告)号:US3584121A

    公开(公告)日:1971-06-08

    申请号:US3584121D

    申请日:1968-02-28

    摘要: A STABLE, NEUTRAL SOLUTION (PH6.5-8) OF BOVINE INSULIN HAVING A QUICK-ACTING BLOOD-SUGAR LOWERING EFFECT. THE SOLUTION MAY ALSO CONTAIN INSULIN OF OTHER TYPES (ORGIN) OR LONG-ACTING INSULIN MATERIAL. BOVINE INSULIN, WHICH TENDS TO PRECIPITATE AT NEUTRAL PH VALUES, IS RETAINED IN SOLUTION BY THE CORPRESENCE OF FROM 0.15% TO 0.5% (W./V.) OF PHENOL OR CRESOL AND OF ZINC IN THE AMOUNT OF FROM 0.3 TO 0.8% BY WEIGHT OF THE INSULIN. SODIUM CHORIDE AND SIMILAR ELECTROLYTES ARE EXCLUDED, AND THE SOLUTION IS MADE ISOTONIC WITH GLYCEROL OR GLUCOSE OR OTHER CARBOHYDRATES WHICH ARE NOT ELECTROLYTICALLY DISSOCIATD IN AQUEOUS SOLUTION. HOWEVER, A PHOSPHATE BUFFER, ESPECIALLY SODIUM PHOSPHATE IS PERMISSIBLE AND DESIRABLE, AND INCREASES THE SOLUBILITY OF THE BOVINE INSULIN.